Five-year results from entry into the BEVORDEX trial
| DEX-implant (46 eyes) | Bevacizumab (42 eyes) | P value | |
| BCVA at the end of trial (2 years) | 62.4 (14.6) | 65.9 (13) | 0.38 |
| VA at 5 years, letters (CI)* | 58.5 (55.1 to 61.9) | 59.5 (57.4 to 63.6) | 0.51 |
| Proportion of eyes who gained ≥10 letters from baseline to 5 years, n (%)* | 14 (30.4) | 14 (33.3) | 0.78 |
| Mean change in vision from baseline, letters (CI)* | 1.8 (−1.6 to 5.3) | 2.7 (0.62 to 6.94) | 0.40 |
| Mean CMT at end of study, µm (CI)* | 329 (265 to 452) | 358 (286 to 415) | 0.36 |
| Mean CMT at 5 years, µm (CI)* | 327 (289 to 367) | 332 (293 to 371) | 0.87 |
| Mean change in CMT (from baseline to 5 years), µm (CI)* | −150 (−199 to −100) | −173 (−232 to −121) | 0.23 |
| Paired t-test (end of study to 5 years) | 0.87 | 0.81 |
*Last observation carried forward.
BCVA, best corrected visual acuity; CMT, central macular thickness; DEX, dexamethasone; VA, visual acuity (obtain from patient file).